Navigation Links
Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
Date:4/10/2013

Alachua, FL (PRWEB) April 10, 2013

Nanotherapeutics, Inc., announced it has been awarded a Department of Defense’s (DOD) contract to establish Medical Countermeasures Advanced Development and Manufacturing (MCM ADM) capability dedicated to meet the needs of the DOD. The MCM ADM capabilities established by Nanotherapeutics will allow the DOD to more efficiently and expeditiously develop Medical Countermeasures (MCM) to protect and treat military populations against chemical, biological, radiological, and nuclear (CBRN) attacks and outbreaks of naturally occurring emerging and genetically engineered infectious diseases.

The contract was granted to Nanotherapeutics, as the prime contractor, and its industry partners after a highly competitive bid process. The ultimate goal for the award is to reduce the overall time and cost associated with the development and manufacturing of Food and Drug Administration approved MCMs.

Headquartered in Alachua, FL, Nanotherapeutics will integrate into a new state-of-the-art facility flexible, single use, disposable equipment that can provide our military’s national security requirements for MCMs now and in the foreseeable future.

Nanotherapeutics has assembled a world class team of partners from throughout the United States to apply new biomanufacturing technologies with existing manufacturing capabilities for small molecule and biologic products that will provide the DOD with the ability to rapidly respond to CBRN events.

About Nanotherapeutics
Nanotherapeutics, Inc. is a privately held biopharmaceutical company with a major focus on developing a diversified proprietary pipeline of products having both biodefense and medical applications. Products under development include biodefense medical countermeasures, CNS, wound healing, addiction and pain, oncology, anti-infectives, vaccines and orthopedics. The Company has one FDA cleared injectable biologic, NanoFUSE® DBM used by orthopedic surgeons as bone graft filler. Nanotherapeutics has in-house cGMP manufacturing, formulation, and expertise in pre-clinical and clinical product development as well as clinical trial management to support its products. Established in 1999, the Company employs several proprietary platform technologies to manipulate and enhance the properties of drug candidates. For more information, visit the Company website at http://www.nanotherapeutics.com.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10611645.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Selenium, Ltd. Awarded $500,000 SBIR Grant for Biofouling Prevention Technology
2. BioPharm Insight Journalist Awarded Fellowship by Association of Health Care Journalists
3. Cellular Dynamics and Coriell Institute for Medical Research Awarded Multi-Million Dollar Grants from California Institute for Regenerative Medicine to Manufacture and Bank Stem Cell Lines
4. Boston Heart Diagnostics Awarded $450,000 in Tax Incentives from the Massachusetts Life Sciences Center
5. S&D Marketing Advertising Awarded WBENC Certification
6. Island Abbey Foods Ltd CEO John Rowe Has Been Awarded the 2013 Food Industry Leadership Award by Food in Canada Magazine
7. Infinata's BioPharm Insight Journalist Awarded Fellowship by Association of Health Care Journalists
8. Fidelis Companies Certifies 14 Recruiters; Certified Personnel Consultant (CPC) and Certified Temporary-Staffing Specialist (CTS) Designation from NAPS Awarded
9. Boyd Coatings Awarded Workforce Training Grant
10. PNNL awarded $2.8 million to keep troops cool while using less fuel
11. University of Minnesota awarded $28 million grant to lead microelectronics development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... Frederick ... a range of emerging bio and technology start-ups, is hosting “Celebration Friday” (a ... double event will start with libations and networking at 3:30 p.m. at FITCI’s ...
(Date:4/20/2017)... , April 20, 2017  Eli Lilly and ... 2 data evaluating galcanezumab for the prevention of migraine ... which will take place April 22-28, 2017, in ... present four abstracts at AAN, including safety and patient ... factors associated with a reduction in monthly migraine headache ...
(Date:4/20/2017)... April 20, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) ... at the International Liver Congress ("ILC") 2017 of the European ... Amsterdam on the positive effects of PBI-4050 ... of obesity and metabolic syndrome. ... According to Dr. Lyne Gagnon, Vice-President of R&D Pre-clinical ...
(Date:4/20/2017)... Dutch philosopher Koert van Mensvoort - founder of the Next Nature Network ... - has written a ,Letter to Humanity, in support of International ... a slave and victim to its own technology, but to employ technology to ... ... – founder of the Next Nature Network and Fellow of ‘Next Nature’ at ...
Breaking Biology Technology:
(Date:3/24/2017)... MILAN , March 24, 2017 The Controller ... Deputy Controller Mr. Abdulla Algeen have received the prestigious international ... Continue Reading ... ... small picture) and Deputy Controller Abdulla Algeen (small picture on the right) ...
(Date:3/22/2017)... 21, 2017 Optimove , provider ... retailers such as 1-800-Flowers and AdoreMe, today announced ... and Replenishment. Using Optimove,s machine learning algorithms, these ... and replenishment recommendations to their customers based not ... of customer intent drawn from a complex web ...
(Date:3/13/2017)... , March 13, 2017 Future of security: Biometric Face ... ... DERMALOGs Face Matching enables to match face pictures against ... basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face Matching ...
Breaking Biology News(10 mins):